- Home
- RRGB vs GNLX Comparison
RRGB vs GNLX Comparison
Compare RRGB & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RRGB
- GNLX
- Stock Information
- Founded
- RRGB 1969
- GNLX 2001
- Country
- RRGB United States
- GNLX United States
- Employees
- RRGB N/A
- GNLX N/A
- Industry
- RRGB Restaurants
- GNLX Biotechnology: Pharmaceutical Preparations
- Sector
- RRGB Consumer Discretionary
- GNLX Health Care
- Exchange
- RRGB Nasdaq
- GNLX Nasdaq
- Market Cap
- RRGB 88.7M
- GNLX 109.4M
- IPO Year
- RRGB 2002
- GNLX 2023
- Fundamental
- Price
- RRGB $5.65
- GNLX $3.38
- Analyst Decision
- RRGB Strong Buy
- GNLX Strong Buy
- Analyst Count
- RRGB 4
- GNLX 4
- Target Price
- RRGB $11.88
- GNLX $17.75
- AVG Volume (30 Days)
- RRGB 350.7K
- GNLX 152.0K
- Earning Date
- RRGB 08-21-2025
- GNLX 08-13-2025
- Dividend Yield
- RRGB N/A
- GNLX N/A
- EPS Growth
- RRGB N/A
- GNLX N/A
- EPS
- RRGB N/A
- GNLX N/A
- Revenue
- RRGB $1,252,370,000.00
- GNLX N/A
- Revenue This Year
- RRGB N/A
- GNLX N/A
- Revenue Next Year
- RRGB N/A
- GNLX N/A
- P/E Ratio
- RRGB N/A
- GNLX N/A
- Revenue Growth
- RRGB N/A
- GNLX N/A
- 52 Week Low
- RRGB $2.50
- GNLX $1.60
- 52 Week High
- RRGB $7.05
- GNLX $5.89
- Technical
- Relative Strength Index (RSI)
- RRGB 56.69
- GNLX 63.14
- Support Level
- RRGB $5.88
- GNLX $2.80
- Resistance Level
- RRGB $6.89
- GNLX $3.61
- Average True Range (ATR)
- RRGB 0.42
- GNLX 0.21
- MACD
- RRGB -0.05
- GNLX 0.05
- Stochastic Oscillator
- RRGB 61.14
- GNLX 73.26
About RRGB Red Robin Gourmet Burgers Inc.
Red Robin Gourmet Burgers Inc is a restaurant operator. The company develops, operates, and franchises casual-dining restaurants and fast-casual restaurants in North America. Its brands are Red Robin, Red Robin Gourmet Burgers, Red Robin America's Gourmet Burgers and Spirits, Red Robin Burger Works, YUMMM, Red Robin Gourmet Burgers and Brews, and Red Robin Royalty names and logos. The company's revenue consists of sales from restaurant operations, gift card breakage, franchise royalties and fees, and other miscellaneous revenue. The company has one operating and one reportable segment: restaurants.
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.